|1.||Bressler, Neil M: 22 articles (02/2010 - 01/2002)|
|2.||Schmidt-Erfurth, Ursula: 21 articles (08/2014 - 09/2002)|
|3.||Hasan, Tayyaba: 15 articles (05/2015 - 03/2003)|
|4.||Pogue, Brian W: 15 articles (05/2015 - 05/2002)|
|5.||Bressler, Susan B: 13 articles (05/2006 - 10/2002)|
|6.||Chen, Bin: 12 articles (03/2015 - 03/2003)|
|7.||Miller, Joan W: 12 articles (07/2014 - 07/2002)|
|8.||Kaiser, Peter K: 12 articles (05/2012 - 03/2003)|
|9.||Slakter, Jason S: 11 articles (05/2012 - 02/2002)|
|10.||Rosenfeld, Philip J: 11 articles (01/2009 - 08/2002)|
12/01/2007 - "Verteporfin therapy of subfoveal occult choroidal neovascularization in AMD using delayed light application: one-year results of the VALIO Study."
05/01/2001 - "Other secondary outcomes, including visual acuity letter score worse than 34 (approximate Snellen equivalent of 20/200 or worse), mean change in visual acuity letter score, development of classic choroidal neovascularization, progression of classic choroidal neovascularization and size of lesion, favored the verteporfin-treated group at both the month 12 and month 24 examination for both the entire study group and the subgroup of cases with occult with no classic choroidal neovascularization at baseline. "
07/01/2007 - "More over the quality assurance regulations for the photodynamic treatment of choroidal neovascularizations with Verteporfin were modified including the treatment of occult lesions and implementing a simplified classification of extra- and subfoveal lesions. "
01/01/2006 - "Nineteen consecutive patients with predominantly classic choroidal neovascularization (CNV) in AMD were treated with 6 mg/m2 verteporfin given as bolus infusion. "
12/01/2005 - "To evaluate the time course and morphologic features of verteporfin therapy-induced vascular effects using 3-dimensional topographic angiography (TAG) in patients with choroidal neovascularization (CNV). "
|2.||Macular Degeneration (Age-Related Maculopathy)
08/01/2004 - "The Verteporfin in Age-related Macular Degeneration (VAM) Study was designed to provide expanded access to verteporfin therapy after beneficial results for these cases were reported but before regulatory approval in North America. "
02/01/2010 - "Re: Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration."
02/01/2009 - "Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration."
07/01/2008 - "The photosensitizer verteporfin is approved for the therapy of neovascularizations, such as age-related maculopathy. "
01/01/2008 - "Randomized multicenter trial of more intense and standard early verteporfin treatment of neovascular age-related macular degeneration."
|3.||Central Serous Chorioretinopathy
09/01/2009 - "On the basis of the results of this study and available information regarding the expected rate of spontaneous resolution, 30% verteporfin dose seems to be safe and effective in the treatment of acute central serous chorioretinopathy."
01/01/2013 - "Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy."
12/01/2012 - "Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy."
08/01/2012 - "Verteporfin was granted the orphan drug designation for the treatment of chronic or recurrent central serous chorioretinopathy (CSC). "
01/01/2009 - "To report a case of bullous central serous chorioretinopathy associated with subretinal exudates and a tear of the retinal pigment epithelium imaged using spectral domain optical coherence tomography and treated successfully with reduced fluence verteporfin photodynamic therapy. "
10/06/2015 - "Furthermore, verteporfin suppressed the proliferation of other cancer cell lines even in the absence of YAP1, suggesting that verteporfin may be effective against multiple types of solid cancers. "
10/06/2015 - "Although verteporfin accumulated to a greater extent in normal cells than in tumor cells in vivo, experiments with cultured cells indicated that the normal cells efficiently cleared verteporfin-induced protein oligomers through autophagic and proteasomal pathways. "
05/01/2015 - "The efficacy of verteporfin delivery in tumors is estimated by perfusion CT, providing a noninvasive method of mapping photosensitizer dose."
10/16/2015 - "Recent studies have shown that Verteporfin inhibits YAP without light stimulation in cancer cells. "
03/15/2005 - "Fluorescence microscopic studies indicated that tumor localization of verteporfin changed from predominantly within the tumor vasculature at 15 min after injection, to being throughout the tumor parenchyma at 3 h after injection. "
09/01/2005 - "Verteporfin therapy for choroidal hemangioma: a long-term follow-up."
10/01/2003 - "Verteporfin therapy may be useful in diffuse choroidal hemangiomas."
11/01/2003 - "The present series demonstrates that even limited, low-irradiance, single-spot photodynamic therapy with verteporfin is an effective first-line treatment for choroidal hemangiomas."
11/01/2001 - "Photodynamic therapy with verteporfin is effective in eliminating subretinal fluid and improving vision in patients with circumscribed choroidal hemangioma."
05/01/2013 - "Recurrent leakage after Visudyne photodynamic therapy for the treatment of circumscribed choroidal hemangioma."
|4.||Triamcinolone Acetonide (Azmacort)
|6.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|10.||Indocyanine Green (Cardio-Green)
|1.||Photochemotherapy (Photodynamic Therapy)
|4.||Induced Hyperthermia (Thermotherapy)
|5.||Phototherapy (Light Therapy)